Dabigatran etexilate Recruiting Phase 4 Trials for Pulmonary Embolism (PE) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02596555Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.